Kyntra Bio reports FY2025 revenue $6.4M, net loss $58.2M; cash $109.4M into 2028

KYNTRA BIO, INC.

Full yr 2025 revenue from cont ops $6.4M (vs $29.6M in 2024); net loss $58.2M (vs $153.1M).
Cash, equivalents, investments, and receivables $109.4M as of Dec 31, 2025; runway into 2028.
Phase 2 monotherapy trial of FG-3246 in mCRPC enrolling; interim analysis expected 2H 2026.
Phase 3 protocol for roxadustat in LR-MDS anemia submitted to FDA; start targeted 2H 2026.
Combo trial of FG-3246 + enzalutamide showed median rPFS 7.0 months; data at ASCO GU 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.